-
Revolutionizing AAV Neutralizing Antibody Detection with CRISPR-Cas9 Technology
Editor’s note: Adeno-associated virus (AAV) vector gene therapy holds immense potential for treating genetic disorders. However, the presence of AAV-neutralizing antibodies (NAbs) can hamper its effectiveness. Accurate detection of these…
-
Unraveling the Complexity of Acute Myeloid Leukemia: Insights from Single-Cell Analysis
In November 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——BMC Bioinformatics. The title of the study is “Detection of continuous hierarchical heterogeneity by single-cell surface antigen analysis in the prognosis evaluation of acute myeloid leukaemia”.…
-
Enhancing Early Infection Risk Prediction in Newly Diagnosed Multiple Myeloma: A Nomogram Prognostic Model Approach
Editor’s note: In patients with newly diagnosed multiple myeloma (NDMM), infections pose a significant threat to morbidity and mortality, particularly within the initial months post-diagnosis. Immunoparesis, characterized by reduced levels…
-
Dr.Yanhang Gao’s Team: Non-Invasive Screening for ANA-Positive DILI Patients with AIH-Like Histological Features, Aiding in Precise Liver Biopsy!
Drug-induced liver injury (DILI) can mimic all features of acute and chronic liver diseases, including autoimmune hepatitis (AIH). Both conditions exhibit similarities in serology and histology, including the presence of…
-
Dr.Guohong Han: Combining Targeted Therapy to Reduce Postoperative Liver Cancer Recurrence and Prolong Survival in Cirrhotic Patients with Anticoagulation
Hepatology Digest: Liver cancer immunotherapy has been a major focus of this year’s conference, particularly the research presented on June 23rd regarding adjuvant targeted immunotherapy for high-risk liver cancer recurrence following…
-
Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections
Currently, there is limited research on the natural history of disease in patients with chronic hepatitis B in the “gray zone,” and there is still debate about the necessity of…
-
Dr. Jun Li’s Team: ETS2 as a Potential New Target for the Diagnosis and Treatment of HBV-ACLF, Alleviating Liver Failure Progression by Suppressing Macrophage Immune Inflammatory Response
Research Introduction Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a complex clinical syndrome characterized by acute decompensation of liver function on the basis of chronic hepatitis B, often accompanied…
-
Dr. George-Lau: Advances and Reflections on Hepatitis B and Hepatitis D New Therapies
Hepatology Digest: Can you talk about the research developments at this conference that you find particularly noteworthy? Dr. George-Lau: There are many small molecule drugs under investigation for hepatitis B, such…
Connecting Medical Expertise through Media